There have been no open-market insider trades at Inmune Bio, Inc. in the last 12 months.
Big money check: 83 institutions held INMB as of Q2 2026, and funds were split between buying and selling. Quarter by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 30, 2024 | Moss David J | CFO | Buy | 10,000 | $5.29 | $53K | SEC |
| Sep 16, 2024 | Tesi Raymond Joseph | CEO | Buy | 15,380 | $6.38 | $98K | SEC |
| Sep 16, 2024 | Moss David J | CFO | Buy | 7,690 | $6.38 | $49K | SEC |
| Jun 26, 2024 | Juda Scott | Director | Buy | 5,000 | $7.27 | $36K | SEC |
| Apr 24, 2024 | Moss David J | CFO | Buy | 18,028 | $8.32 | $150K | SEC |
| Apr 24, 2024 | Tesi Raymond Joseph | CEO | Buy | 18,028 | $8.32 | $150K | SEC |
| Apr 24, 2024 | Lowdell Mark William | Executive Officer | Buy | 14,423 | $8.32 | $120K | SEC |
| Apr 24, 2024 | Juda Scott | Director | Buy | 29,603 | $8.32 | $246K | SEC |
| Nov 13, 2023 | Juda Scott | Director | Buy | 7,000 | $6.95 | $49K | SEC |
| Jul 14, 2023 | Schroeder Timothy j | Director | Sell | 10,000 | $11.01 | $110K | SEC |
| Mar 20, 2023 | Moss David J | CFO | Buy | 2,500 | $6.43 | $16K | SEC |
There were no open-market insider trades in INMB in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
83 investment managers reported holding INMB in SEC Form 13F filings for Q2 2026.
No congressional trades in INMB were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).